{"id":"W3023075010","doi":"10.1016/j.amjmed.2020.03.045","title":"Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI","year":2020,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Janssen Pharmaceuticals; Duke Clinical Research Institute; St. Jude Medical; Novo Nordisk; Daiichi-Sankyo; Ferring Pharmaceuticals; ZonMw; Bayer HealthCare; Belvoir Media Group; Medicines Company; Regado Biosciences; Bayer Fund; Boston Scientific Corporation; Bristol-Myers Squibb; Cleveland Clinic; American College of Cardiology Foundation; Servier; Gilead Sciences; Center for Social Inclusion; Medtronic; ZOLL Medical Corporation; Novartis; Abbott Laboratories; CSL Behring; Pfizer; Icahn School of Medicine at Mount Sinai; Eli Lilly and Company; Biotronik; AstraZeneca; Merck; Mayo Clinic; Boehringer Ingelheim; Amgen; Sanofi","keywords":"Medicine; Dabigatran; Conventional PCI; Warfarin; Dual (grammatical number); Internal medicine; Cardiology; Atrial fibrillation; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001261695,0.001035363,0.004514434,0.0003892814,0.0003185761,0.001910154,0.000660835,0.001093437,0.004576116],"category_scores_gemma":[0.003243054,0.0004558307,0.004170767,0.0004348186,0.0004433592,0.001431052,0.000636973,0.003301123,0.0004738581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009844791,"about_ca_system_score_gemma":0.001064142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002424321,"about_ca_topic_score_gemma":0.004830095,"domain_scores_codex":[0.998754,0.0004112578,0.000182978,0.000289291,0.00008623552,0.0002762844],"domain_scores_gemma":[0.998444,0.0006314971,0.0002556038,0.00009205563,0.00008242824,0.0004943582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9656127,0.001973473,0.003124962,0.0006376429,0.003611007,0.0000764826,0.00007638769,0.000601775,0.001673843,0.0002225424,0.0004257016,0.0219635],"study_design_scores_gemma":[0.5395737,0.3031668,0.1120254,0.0009237665,0.028471,0.0003998757,0.000833192,0.006676596,0.002173641,0.001897184,0.003650964,0.0002078597],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873366,0.008120241,0.0004562955,0.0004906659,0.0005518123,0.0001928927,0.0003319524,0.00002753176,0.002492087],"genre_scores_gemma":[0.9947919,0.002857421,0.0004191858,0.0003754265,0.0004074576,0.0001203858,0.0003753007,0.00001072234,0.0006420455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004576116,"threshold_uncertainty_score":0.01530862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09700152814184801,"score_gpt":0.3962920735313843,"score_spread":0.2992905453895363,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}